Amgen annual net debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Amgen Net Debt Growth & History (AMGN)
Amgen's net debt was $46.31B for fiscal 2025.
View full Amgen company overviewAmgen annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $46.31B | −$2.60B | −5.32% |
| 2024 | 2024-12-31 | $48.91B | −$5.57B | −10.23% |
| 2023 | 2023-12-31 | $54.48B | $22.47B | +70.19% |
| 2022 | 2022-12-31 | $32.01B | $6.02B | +23.17% |
| 2021 | 2021-12-31 | $25.99B | −$1.19B | −4.37% |
| 2020 | 2020-12-31 | $27.18B | $2.79B | +11.42% |
| 2019 | 2019-12-31 | $24.39B | −$2.59B | −9.60% |
| 2018 | 2018-12-31 | $26.98B | −$4.56B | −14.45% |
| 2017 | 2017-12-31 | $31.54B | $187.0M | +0.60% |
| 2016 | 2016-12-31 | $31.36B | $4.07B | +14.92% |
| 2015 | 2015-12-31 | $27.29B | $301.0M | +1.12% |
| 2014 | 2014-12-31 | $26.98B | −$1.34B | −4.73% |
| 2013 | 2013-12-31 | $28.32B | $5.05B | +21.70% |
| 2012 | 2012-12-31 | $23.27B | $8.79B | +60.70% |
| 2011 | 2011-12-31 | $14.48B | $6.89B | +90.88% |
| 2010 | 2010-12-31 | $7.59B | −$130.0M | −1.68% |
| 2009 | 2009-12-31 | $7.72B | $5.23B | +210.79% |
| 2008 | 2008-12-31 | $2.48B | — | — |
Amgen quarterly net debt
Q4.08
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q4.11
Q4.12
Q1.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $43.31B | −$4.86B | −10.09% |
| Q1 2026 | 2026-03-31 | $45.28B | −$3.29B | −6.77% |
| Q4 2025 | 2025-12-31 | $46.31B | −$2.60B | −5.32% |
| Q3 2025 | 2025-09-30 | $45.14B | −$6.25B | −12.15% |
| Q2 2025 | 2025-06-30 | $48.18B | −$5.17B | −9.69% |
| Q1 2025 | 2025-03-31 | $48.57B | −$5.74B | −10.57% |
| Q4 2024 | 2024-12-31 | $48.91B | −$5.57B | −10.23% |
| Q3 2024 | 2024-09-30 | $51.39B | $25.66B | +99.74% |
| Q2 2024 | 2024-06-30 | $53.34B | $26.05B | +95.43% |
| Q1 2024 | 2024-03-31 | $54.31B | $24.28B | +80.83% |
| Q4 2023 | 2023-12-31 | $54.48B | $22.47B | +70.19% |
| Q3 2023 | 2023-09-30 | $25.73B | −$3.48B | −11.90% |
| Q2 2023 | 2023-06-30 | $27.30B | −$4.02B | −12.85% |
| Q1 2023 | 2023-03-31 | $30.04B | −$291.0M | −0.96% |
| Q4 2022 | 2022-12-31 | $32.01B | $6.02B | +23.17% |
| Q3 2022 | 2022-09-30 | $29.20B | $3.59B | +14.03% |
| Q2 2022 | 2022-06-30 | $31.32B | — | — |
| Q1 2022 | 2022-03-31 | $30.33B | $3.75B | +14.12% |
| Q4 2021 | 2021-12-31 | $25.99B | −$1.19B | −4.37% |
| Q3 2021 | 2021-09-30 | $25.61B | $410.0M | +1.63% |
| Q1 2021 | 2021-03-31 | $26.57B | $2.41B | +9.98% |
| Q4 2020 | 2020-12-31 | $27.18B | $2.79B | +11.42% |
| Q3 2020 | 2020-09-30 | $25.20B | — | — |
| Q2 2020 | 2020-06-30 | $25.08B | −$507.0M | −1.98% |
| Q1 2020 | 2020-03-31 | $24.16B | −$1.99B | −7.62% |
| Q4 2019 | 2019-12-31 | $24.39B | −$2.59B | −9.60% |
| Q2 2019 | 2019-06-30 | $25.59B | $1.22B | +5.01% |
| Q1 2019 | 2019-03-31 | $26.15B | $354.0M | +1.37% |
| Q4 2018 | 2018-12-31 | $26.98B | −$4.56B | −14.45% |
| Q3 2018 | 2018-09-30 | $22.47B | −$10.30B | −31.44% |
| Q2 2018 | 2018-06-30 | $24.37B | −$8.07B | −24.87% |
| Q1 2018 | 2018-03-31 | $25.80B | −$4.93B | −16.05% |
| Q4 2017 | 2017-12-31 | $31.54B | $187.0M | +0.60% |
| Q3 2017 | 2017-09-30 | $32.78B | $938.0M | +2.95% |
| Q2 2017 | 2017-06-30 | $32.43B | $1.84B | +6.02% |
| Q1 2017 | 2017-03-31 | $30.73B | −$677.0M | −2.16% |
| Q4 2016 | 2016-12-31 | $31.36B | $4.07B | +14.92% |
| Q3 2016 | 2016-09-30 | $31.84B | $3.30B | +11.58% |
| Q2 2016 | 2016-06-30 | $30.59B | $2.44B | +8.65% |
| Q1 2016 | 2016-03-31 | $31.41B | $3.93B | +14.32% |
| Q4 2015 | 2015-12-31 | $27.29B | $301.0M | +1.12% |
| Q3 2015 | 2015-09-30 | $28.54B | −$768.0M | −2.62% |
| Q2 2015 | 2015-06-30 | $28.16B | −$819.0M | −2.83% |
| Q1 2015 | 2015-03-31 | $27.48B | −$860.0M | −3.03% |
| Q4 2014 | 2014-12-31 | $26.98B | −$1.34B | −4.73% |
| Q3 2014 | 2014-09-30 | $29.30B | $10.39B | +54.98% |
| Q2 2014 | 2014-06-30 | $28.98B | — | — |
| Q1 2014 | 2014-03-31 | $28.34B | $6.97B | +32.65% |
| Q4 2013 | 2013-12-31 | $28.32B | $5.05B | +21.70% |
| Q3 2013 | 2013-09-30 | $18.91B | — | — |
| Q1 2013 | 2013-03-31 | $21.36B | — | — |
| Q4 2012 | 2012-12-31 | $23.27B | $8.79B | +60.70% |
| Q4 2011 | 2011-12-31 | $14.48B | $6.89B | +90.88% |
| Q1 2011 | 2011-03-31 | $9.56B | $9.62B | — |
| Q4 2010 | 2010-12-31 | $7.59B | −$130.0M | −1.68% |
| Q3 2010 | 2010-09-30 | $7.89B | $7.02B | +806.90% |
| Q2 2010 | 2010-06-30 | $7.61B | $6.19B | +437.53% |
| Q1 2010 | 2010-03-31 | −$65.0M | — | — |
| Q4 2009 | 2009-12-31 | $7.72B | $5.23B | +210.79% |
| Q3 2009 | 2009-09-30 | $870.0M | — | — |
| Q2 2009 | 2009-06-30 | $1.42B | — | — |
| Q4 2008 | 2008-12-31 | $2.48B | — | — |
Amgen net debt trends
Over the last five fiscal years, Amgen's net debt increased from $27.18B to $46.31B, a change of $19.13B. The latest reported quarter, Q2 2026, shows $43.31B.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amgen source filings ↗Community posts
Amgen–AstraZeneca combination cuts lung-cancer mortality risk by 58%
Amgen ($AMGN) disclosed detailed Phase 3 results showing that adding Imdelltra to AstraZeneca ($AZN)’s Imfinzi reduced the risk of death by 58% in first-line maintenance treatment of extensive-stage small-cell lung cancer. Median overall su ...
